OBJECTIVES: Hepatitis C (HCV) can lead to serious and costly liver complications including hepatocellular carcinoma and liver transplantation. Physicians have employed a “watch and wait” philosophy, placing their HCV patients in “warehouses” depending on disease genotype (GT), waiting for disease progression or the launch of new treatments. There has been a significant amount of press behind the high prices of new HCV products, but little has been discussed about the cumulative clinical and economic value they bring. One aspect of value is clinical benefit as measured by sustained viral response (SVR) rate. The objective was to determine how the average efficacy, measured by SVR, of HCV treatments changed from November 2013 to April 2014 and its potential impact on clinical and economic outcomes. METHODS: Using IMS Health National Prescription Audit Data, two time periods were defined: the past state of November 2013, when the fewest number of prescriptions for HCV treatments were written; the current state of April 2014, when the greatest number of prescriptions for HCV treatments were written. In order to compare the average SVR rate in these two time points, we calculated a weighted average SVR rate across GTs based on the proportion of patients in each GT and the market share of the following products: sofosbuvir, telaprevir, simeprevir, and boceprevir.  RESULTS: Combining SVR rates with market share and the proportion of patients in each GT, the average SVR rate in November 2013 and April 2014 was 74% and 86%respectively. This 12% increase across GTs was presumably driven by the launch of sofosbuvir.  CONCLUSIONS: There are significant clinical and economic implications of overall improvement in SVR rate including impacts on liver transplant hospitalizations and end of life care. Additional HEOR considerations related to linking SVR rates to these outcomes will be considered further in the poster.